These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 3929314)

  • 41. L-deprenyl in Alzheimer's disease. Preliminary evidence for behavioral change with monoamine oxidase B inhibition.
    Tariot PN; Cohen RM; Sunderland T; Newhouse PA; Yount D; Mellow AM; Weingartner H; Mueller EA; Murphy DL
    Arch Gen Psychiatry; 1987 May; 44(5):427-33. PubMed ID: 3107514
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Tyramine antagonistic properties of AGN 1135, an irreversible inhibitor of monoamine oxidase type B.
    Finberg JP; Tenne M; Youdim MB
    Br J Pharmacol; 1981 May; 73(1):65-74. PubMed ID: 6793119
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pharmacology of MAO B inhibitors: mode of action of (-)deprenyl in Parkinson's disease.
    Youdim MB
    J Neural Transm Suppl; 1986; 22():91-105. PubMed ID: 3097263
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Oral tyramine pressor test and the safety of monoamine oxidase inhibitor drugs: comparison of brofaromine and tranylcypromine in healthy subjects.
    Bieck PR; Antonin KH
    J Clin Psychopharmacol; 1988 Aug; 8(4):237-45. PubMed ID: 3209716
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Inhibition of monoamine oxidase type A, but not type B, is an effective means of inducing anticonvulsant activity in the kindling model of epilepsy.
    Löscher W; Lehmann H; Teschendorf HJ; Traut M; Gross G
    J Pharmacol Exp Ther; 1999 Mar; 288(3):984-92. PubMed ID: 10027835
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Metabolic transformation plays a primary role in the psychostimulant-like discriminative-stimulus effects of selegiline [(R)-(-)-deprenyl].
    Yasar S; Justinova Z; Lee SH; Stefanski R; Goldberg SR; Tanda G
    J Pharmacol Exp Ther; 2006 Apr; 317(1):387-94. PubMed ID: 16352699
    [TBL] [Abstract][Full Text] [Related]  

  • 47. (-)-Deprenyl inhibits tyramine-induced noradrenaline release, but not tyramine-induced dopamine release or potassium-induced noradrenaline release, from rat brain synaptosomes.
    Takahata K; Shimazu S; Yoneda F
    Pharmacol Res; 2004 Mar; 49(3):253-8. PubMed ID: 14726221
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [History of deprenyl--the first selective inhibitor of monoamine oxidase type B].
    Knoll J
    Vopr Med Khim; 1997; 43(6):482-93. PubMed ID: 9503565
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effect of long-term treatment with selective monoamine oxidase A and B inhibitors on dopamine release from rat striatum in vivo.
    Lamensdorf I; Youdim MB; Finberg JP
    J Neurochem; 1996 Oct; 67(4):1532-9. PubMed ID: 8858937
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Monoamine oxidase in pancreatic islets, exocrine pancreas, and liver from rats. Characterization with clorgyline, deprenyl, pargyline, tranylcypromine, and amezinium.
    Lenzen S; Nahrstedt H; Panten U
    Naunyn Schmiedebergs Arch Pharmacol; 1983 Nov; 324(3):190-5. PubMed ID: 6419132
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effects of a tyramine-enriched meal on blood pressure response in healthy male volunteers treated with selegiline transdermal system 6 mg/24 hour.
    Blob LF; Sharoky M; Campbell BJ; Kemper EM; Gilmor MG; VanDenberg CM; Azzaro AJ
    CNS Spectr; 2007 Jan; 12(1):25-34. PubMed ID: 17192761
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Monoamine oxidase in bovine thyroid tissue.
    Masini-Repiso AM; Cabanillas AM; Andrada MC; Coleoni AH
    Horm Metab Res; 1986 Nov; 18(11):750-3. PubMed ID: 3098663
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Relationship between tyramine potentiation and selective inhibition of monoamine oxidase types A and B in the rat vas deferens.
    Finberg JP; Tenne M
    Br J Pharmacol; 1982 Sep; 77(1):13-21. PubMed ID: 6127132
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Recovery of MAO-B enzyme activity after (-)deprenyl (selegiline) pretreatment, measured in vivo.
    Timár J
    Acta Physiol Hung; 1989; 74(3-4):259-66. PubMed ID: 2517980
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Tyramine pressor sensitivity during treatment with the selegiline transdermal system 6 mg/24 h in healthy subjects.
    Azzaro AJ; Vandenberg CM; Blob LF; Kemper EM; Sharoky M; Oren DA; Campbell BJ
    J Clin Pharmacol; 2006 Aug; 46(8):933-44. PubMed ID: 16855078
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The effect of deprenyl, a selective monoamine oxidase B inhibitor, on sleep and mood in man.
    Thornton C; Doré CJ; Elsworth JD; Herbert M; Stern GM
    Psychopharmacology (Berl); 1980; 70(2):163-6. PubMed ID: 6776576
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pharmacodynamics of MDL 72974A: absence of effect on the pressor response to oral tyramine.
    Hinze C; Kaschube M; Hardenberg J
    J Neural Transm Suppl; 1994; 41():371-5. PubMed ID: 7931253
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Characteristics of mitochondrial and synaptosomal monoamine oxidase in monkey brain.
    Egashira T; Yamamoto T; Yamanaka Y
    Jpn J Pharmacol; 1984 Feb; 34(2):211-9. PubMed ID: 6431160
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [The comparative influence of pyrazidol, inkazan and other antidepressant monoamine oxidase inhibitors on the pressor effect of tyramine].
    Andreeva NI; Golovina SM; Faermark MF; Shvarts GIa; Mashkovskiĭ MD
    Farmakol Toksikol; 1991; 54(2):38-40. PubMed ID: 1884793
    [TBL] [Abstract][Full Text] [Related]  

  • 60. R-(-)-deprenyl (Selegiline, Movergan) facilitates the activity of the nigrostriatal dopaminergic neuron.
    Knoll J
    J Neural Transm Suppl; 1987; 25():45-66. PubMed ID: 2828537
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.